VR
Virax Biolabs Group Limited
VRAX · NASDAQ
$2.54 +1.60% (+$0.04)
1M -26.38%
Market Cap $50.4M
P/E Ratio -
Div. Yield -
ROE 73.80%
Piotroski F-Score Weak
2/9Valuation
9 /100
Expensive P/B 6.65x
P/S 4,057.50x
EV/FFO N/A
Growth
62 /100
Stable Book val. growth 6.01%
Rev. growth 13.21%
FCF growth N/A
Profitability
20 /100
Weak Net margin 40,439.10%
Op. margin 51,515.20%
FCF margin 39,263.60%
Quality
0 /100
Poor ROE 73.80%
ROA 60.35%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 9.97x
Debt/Equity 0.05x
Net debt/EBITDA N/A
Stability
12 /100
Unstable Rev. volatility 1,001.69%
EPS volatility 338.60%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about VRAX
Online
About the company
Virax Biolabs Group Limited (VRAX) is a biotechnology company focusing on the research and development of drugs and therapeutic procedures in the field of infectious diseases and immunology.
Sector
Healthcare
Industry
Biotechnology
CEO
James Foster
Employees
26
Headquarters
Lanarkshire
Upcoming events
02 DEC
Earnings
Upcoming earnings report